| Name |
HDACi
|
| Type |
histone modification
|
| Species |
Homo sapiens
|
| Tissue |
bone
|
| Experiment Method |
PCR, Flow cytometry assay, Western blot
|
| Up/Down |
Up
|
| Pro/Anti |
Pro
|
| Funtion Description |
we show that continuous exposure of osteosarcoma cells to low concentrations of HDACi LBH589 (Panobinostat) over a three-week period induces terminal osteoblast differentiation and irreversible senescence without inducing cell death. Remarkably, trans
|
| Regulation Gene |
null
|
| Year |
2013
|
| Pubmed ID |
23533324
|
| Title |
Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells.
|
| Drug |
LBH589 (Panobinostat)
|
| Disease |
Osteosarcoma
|
| Environment Factors |
NA
|
| Circulating |
NA
|
| Variant |
NA
|
| High-throughput |
NA
|